IVABRADINE HYDROCHLORIDE | A213442 | ZYDUS PHARMACEUTICALS USA INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
AMGEN INC. et al v. ZYDUS PHARMACEUTICALS (USA) INC. et al 4 patentsANDA 213442ivabradine | D.N.J. | 2020-01-21 | Terminated 2020-05-08 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$0.7713
per ea
Lowest NADAC/Unit
$0.7371
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 70710147106IVABRADINE HCL 5 MG TABLET | $0.7713 | EA | Generic | — | 2026-06-17 |
| 70710147206IVABRADINE HCL 7.5 MG TABLET | $0.7371 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.